Cancer Stem Cell News 7.05 February 7, 2018 | |
| |
TOP STORYTamoxifen directly bound and activated estrogen receptor alpha (ERα36) to enhance the stemness and metastasis of breast cancer cells via transcriptional stimulation of aldehyde dehydrogenase 1A1 (ALDH1A1). [Cell Res] Full Article | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Scientists discovered that miR-34c-5p, a microRNA central to the senescence regulation network, was significantly down-regulated in AML (non-acute promyelocytic leukemia, non-APL) stem cells compared to that in normal hematopoietic stem cells. [Leukemia] Abstract TRIM59 Promotes Gliomagenesis by Inhibiting TC45 Dephosphorylation of STAT3 Investigators demonstrated that tripartite motif-containing protein 59 (TRIM59) acts as a new downstream effector of epidermal growth factor receptor signaling by regulating STAT3 activation in glioblastoma. [Cancer Res] Abstract Compared with free lovastatin (LV), cerasome-loaded-LV nanohybrids showed cytotoxicity to MDA-MB-231 CSCs in a dose- and time-dependent manner as measured by the AlamarBlue viability assay. [ACS Appl Mater Interfaces] Abstract GTP cyclohydrolase 1 (GCH1) was expressed in glioblastomas (GBMs) with elevated but not exclusive RNA and protein in BTICs in comparison to non-BTICs. Overexpression of GCH1 in GBM cells increased cell growth in vitro and decreased survival in an intracranial GBM mouse model. [Neuro Oncol] Abstract Investigators found that chronic arsenic exposure endows urothelial cells with malignant stemness properties including increased expression of stemness-related factors such as SOX2, sphere formation, self-renewal, invasion, and chemo-resistance. [Int J Cancer] Abstract In response to glucose restriction, the authors found that nuclear translocation of the glycolic enzyme, pyruvate kinase M2 (PKM2), helped cancer cells survive under the metabolic stress. [Cancer Lett] Abstract Investigators demonstrated that the ratio of cancer stem cells is increased in ER stress-resistant melanoma cells, which inhibit ER stress-induced apoptosis and promote tumorigenesis. [J Invest Dermatol] Abstract The authors found a significant difference in the expression of connexin 43 and SUMO1 between cancer stem cells and non-cancer stem cells in liver cancer. [Int J Oncol] Abstract | |
| |
REVIEWSN6-Methyladenosine Links RNA Metabolism to Cancer Progression Scientists summarize the regulation and function of N6-methyladenosine in human carcinogenesis. [Cell Death Dis] Full Article The authors review the current findings regarding the epigenetic regulatory mechanisms of neural stem cell (NSC) fate in the developing brain, as well as those of glioblastoma multiforme (GBM) and glioblastoma stem cells (GSCs). Considering the similarities between NSCs and GSCs, they also discuss potential new strategies for GBM treatment. [Cell Biol Toxicol] Abstract Visit our reviews page to see a complete list of reviews in the cancer stem cell research field. | |
| |
INDUSTRY NEWSPharmAbcine Inc. announced it has entered into a collaborative agreement with MSD, through a subsidiary, to evaluate PharmAbcine’s anti-VEGFR2 mAb, TTAC-0001, in combination with MSD’s anti-programmed death receptor-1 therapy, KEYTRUDA®, in patients with recurrent glioblastoma multiforme and metastatic triple-negative breast cancer. [PharmAbcine Inc. (Business Wire, Inc.)] Press Release Cellectar Receives USPTO Notice of Allowance for Patent Covering Use of CLR 131 in Multiple Myeloma Cellectar Biosciences announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for U.S. Patent Application No. 15/095,641, entitled “Alkylphosphocholine Analogs for Multiple Myeloma Imaging and Therapy,” which covers a method of use for CLR 131, the company’s lead radiotherapeutic Phospholipid Drug Conjugate™ in multiple myeloma. [Cellectar Biosciences] Press Release Verastem, Inc. announced it has submitted a New Drug Application to the FDA seeking full approval for its lead product candidate duvelisib, a first-in-class oral dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, for the treatment of relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and accelerated approval for the treatment of relapsed or refractory follicular lymphoma. [Verastem, Inc.] Press Release | |
| |
POLICY NEWSPeace is a dangerous cause to fight for in Turkey right now. In the latest blow to academics, 11 members of the Turkish Medical Association, including its president, Raşit Tükel, were arrested in early-morning raids. [Nature News] Editorial Japanese Researchers Say Science-Budget Hike Isn’t Enough Japan will sharply increase funding for science and technology in 2018 after years of stagnant support for the sector. But some scientists and policy experts worry the boost is too little to make up for more than a decade of lackluster science funding. [Nature News] Editorial Pubmed Commons Closes Its Doors to Comments The US National Institutes of Health announced that it will discontinue PubMed Commons, a tool that allows scientists to comment on articles indexed in the agency’s popular PubMed database of biomedical literature. The agency said low levels of engagement and the growth of alternate venues for public discussion of published papers contributed to its decision to close PubMed Commons after five years. [Nature News] Editorial Nature Journals Tighten Rules on Non-Financial Conflicts What makes a conflict of interest in science? Definitions differ, but broadly agree on one thing: an influence that can cloud a researcher’s objectivity. For some people, that influence can be money. But there are other influences that can interfere, such as institutional loyalty, personal beliefs and ambition. [Nature News] Editorial
| |
EVENTSNEW The New York Stem Cell Foundation (NYSCF) Conference 2018 Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Senior Bioinformatician – Cancer Research (Children´s Cancer Research Institute) NEW PhD Program – Cellular Biology (Institut de Génétique et de Biologie Moléculaire et Cellulaire) Postdoctoral Fellow – Cancer Biology (Johns Hopkins University) Postdoctoral Fellow – Cancer Stem Cell Biology (Wake Forest Baptist Comprehensive Cancer Center) Postdoctoral Associate – Cerebral Organoids and Tumor Stem Cell Biology (Weill Cornell Medicine) Postdoctoral Scholarship – Translational Cancer Stem Cell Biology (Lund University) Postdoctoral Positions – Gene Regulation and/or Cancer Biology (University of North Carolina) Postdoctoral Fellow – Cancer Biology (University of Pennsylvania) Postdoctoral Associate – Control of Metastasis/Cancer Stem Cell Regulation (University of Miami) Faculty Positions – Cancer and Stem Cell Biology (Sun Yat-Sen University) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|